万邦医药 (301520)

Anhui Wanbang Pharmaceutical Technology Co.,Ltd.

ASZ

Tags

Contract Research Organization (CXO)DeepSeekMedical ServicesMicro Cap StocksR&DBelow IPO PriceShenzhen Recently Listed StocksSZSE Medicine Equal Weight IndexShenzhen A-Share Pharmaceutical IndexChiNext Composite IndexCSI All-share Pharmaceutical Sector IndexScientific Research IndexAnhui

K-Line Chart

No K-line data available

Company NameAnhui Wanbang Pharmaceutical Technology Co., Ltd.
Listing Date2023-09-25
Issue Price67.88RMB
Registered Capital6666.666710k RMB
Legal RepresentativeTao Chunlei
Registered AddressNo. 299 Huolongdi Road, High-Tech Zone, Hefei City, Anhui Province
IndustryMedical Services
Main BusinessA comprehensive CRO enterprise providing both pharmaceutical research and clinical research services.
Company ProfileAnhui Wanbang Pharmaceutical Technology Co., Ltd. is a comprehensive CRO enterprise providing both pharmaceutical research and clinical research services. It is one of the early CRO companies in China offering drug R&D services. The company started with clinical research services and subsequently established subsidiaries such as the Clinical Department, Bioanalysis Department, Pharmaceutical Department, and Yiran Biology, possessing the capability to provide full-process services covering pharmaceutical research and clinical research. Since the release of the '722 Clinical Trial Inspection' policy in 2015, the company has undertaken over 200 pharmaceutical research and clinical research service projects. Leveraging its technical strengths and service quality, it has successfully obtained 68 acceptance numbers, passed 48 on-site inspections or received inspection exemptions from the National Medical Products Administration (NMPA), and secured 44 approvals. The company has received numerous honors including High-Tech Enterprise, Top 20 Chinese Pharmaceutical Outsourcing Companies, Chinese Pharmaceutical Law-Abiding and Integrity Enterprise, Hefei High-Tech Zone Gazelle Enterprise, Anhui Provincial Enterprise Technology Center, and Anhui Provincial Specialized, Refined, Distinctive, and Innovative SME. It holds strong brand recognition and market influence among CRO enterprises.

Stock Details

1. Key Indicators

  • Total Shares(W): 6666.67
  • Circulating A-Shares(W): 2242.30
  • Earnings Per Share(RMB): 0.5000
  • Net Assets Per Share(RMB): 22.6915
  • Operating Revenue(W RMB): 20942.59
  • Total Profit(W RMB): 3038.73
  • Net Profit Attributable to Parent(W RMB): 3311.06
  • Net Profit Growth Rate(%): -57.44
  • Weighted Return on Equity(%): 2.2100
  • Operating Cash Flow Per Share(RMB): 0.0950
  • Undistributed Profit Per Share(RMB): 5.7225
  • Capital Reserve Per Share(RMB): 15.5896

2. Main Business

The main business covers:

  • Pharmaceutical Research
  • Clinical Research Services

3. Company Basic Information

  • Company Name: Anhui Wanbang Pharmaceutical Technology Co., Ltd.
  • Listing Date: 2023-09-25
  • Industry: Research and Experimental Development
  • Address: No. 299 Huolongdi Road, High-tech Zone, Hefei City, Anhui Province
  • Website: www.ahwbyy.cn
  • Company Profile: Wanbang Pharmaceutical was established as a joint stock company through the overall transformation of Wanbang Co., Ltd. On August 6, 2019, all shareholders of Wanbang Co., Ltd. signed the "Sponsor Agreement", agreeing to convert the audited net assets of Wanbang Co., Ltd. as of May 31, 2019, which amounted to 33.3827 million yuan, into shares to establish a joint stock company. The company's share capital is 10 million yuan, with a par value of 1 yuan per share, and the portion of net assets exceeding the share capital is recorded as capital reserve. On August 22, 2019, Wanbang Pharmaceutical held its founding meeting and the first interim shareholders' meeting in 2019, where relevant proposals for the overall transformation of Wanbang Co., Ltd. into a joint stock company were reviewed and passed. For the overall transformation into a joint stock company, Wanbang Co., Ltd. hired an accounting firm and an asset appraisal agency for auditing and evaluation. According to the audit, as of May 31, 2019, the net assets of Wanbang Co., Ltd. were 33.3827 million yuan. The evaluated net asset value of Wanbang Co., Ltd. was higher than the audited net assets. On September 5, 2019, Wanbang Pharmaceutical obtained the business license (Unified Social Credit Code: 91340100784936148J) issued by the Hefei Market Supervision Administration.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Shanghai Tianyidao Investment Management Co., Ltd. - Tianyidao Shenghong Wenjian No. 7 Private Securities Investment Fund Private Securities Investment Fund 114.87 5.12

5. Concept Sectors

  • Food Safety
  • CXO Concept
  • Innovative Drugs
  • Weight Loss Drugs
  • DeepSeek
  • Margin Trading & Securities Lending
  • Micro Cap Stocks
  • Below IPO Price

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information